- Home
- QXO vs IONS Comparison
QXO vs IONS Comparison
Compare QXO & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QXO
- IONS
- Stock Information
- Founded
- QXO 1988
- IONS 1989
- Country
- QXO United States
- IONS United States
- Employees
- QXO N/A
- IONS N/A
- Industry
- QXO EDP Services
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- QXO Technology
- IONS Health Care
- Exchange
- QXO Nasdaq
- IONS Nasdaq
- Market Cap
- QXO 5.7B
- IONS 5.9B
- IPO Year
- QXO N/A
- IONS 1991
- Fundamental
- Price
- QXO $21.88
- IONS $43.27
- Analyst Decision
- QXO Strong Buy
- IONS Buy
- Analyst Count
- QXO 5
- IONS 16
- Target Price
- QXO $33.25
- IONS $58.25
- AVG Volume (30 Days)
- QXO 13.8M
- IONS 1.9M
- Earning Date
- QXO 08-13-2025
- IONS 07-31-2025
- Dividend Yield
- QXO 121.29%
- IONS N/A
- EPS Growth
- QXO N/A
- IONS N/A
- EPS
- QXO N/A
- IONS N/A
- Revenue
- QXO $55,945,000.00
- IONS $717,253,000.00
- Revenue This Year
- QXO $8,691.52
- IONS $7.98
- Revenue Next Year
- QXO $139.58
- IONS $16.09
- P/E Ratio
- QXO N/A
- IONS N/A
- Revenue Growth
- QXO 0.21
- IONS N/A
- 52 Week Low
- QXO $10.61
- IONS $23.95
- 52 Week High
- QXO $157.28
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- QXO 60.77
- IONS 80.44
- Support Level
- QXO $21.64
- IONS $39.37
- Resistance Level
- QXO $24.69
- IONS $43.71
- Average True Range (ATR)
- QXO 1.05
- IONS 1.35
- MACD
- QXO -0.22
- IONS 0.45
- Stochastic Oscillator
- QXO 47.77
- IONS 95.02
About QXO QXO Inc. Common Stock
QXO Inc provides technology solutions, primarily to clients in the manufacturing, distribution, and service sectors. It provides consulting and professional services, specialized programming, training, and technical support. It also offers solutions for accounting, financial reporting, enterprise resource planning, warehouse management systems, customer relationship management, business intelligence, and other applications.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.